Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses
Dengue fever, caused by four serotypes of a mosquito-borne virus, is a growing problem in tropical countries. Currently, there is no treatment or vaccine. We evaluated safety and immunogenicity of two doses, given six months apart, of seven formulations of dengue tetravalent live-attenuated vaccine...
Gespeichert in:
| Veröffentlicht in: | The American journal of tropical medicine and hygiene 2002-03, Vol.66 (3), p.264-272 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 272 |
|---|---|
| container_issue | 3 |
| container_start_page | 264 |
| container_title | The American journal of tropical medicine and hygiene |
| container_volume | 66 |
| creator | Sabchareon, A Lang, J Chanthavanich, P Yoksan, S Forrat, R Attanath, P Sirivichayakul, C Pengsaa, K Pojjaroen-Anant, C Chokejindachai, W Jagsudee, A Saluzzo, JF Bhamarapravati, N |
| description | Dengue fever, caused by four serotypes of a mosquito-borne virus, is a growing problem in tropical countries. Currently, there is no treatment or vaccine. We evaluated safety and immunogenicity of two doses, given six months apart, of seven formulations of dengue tetravalent live-attenuated vaccine (containing different concentrations of the component viruses) versus placebo in 59 flavivirus-seronegative Thai adults. The first dose was the more reactogenic. Most volunteers experienced clinically moderate fever, headache, myalgia, eye pain or rash 7-11 days after injection, generally lasting three days or less. Modest decreases in platelets and neutrophils were observed. After one dose, 58% of dengue recipients seroconverted (neutralizing antibody level > or = 1:10) against > or = 3 serotypes; 35% seroconverted against all four. After the second dose, seroconversion was 76% and 71%, respectively. All subjects seroconverted to serotype 3 after one dose. Serotype 4 elicited the lowest primary response but the highest increase in seroconversion after the second dose. |
| doi_str_mv | 10.4269/ajtmh.2002.66.264 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71936584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71936584</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-36ee505efce7d333c0a7071a9b2f7d393d78584f543d076c0a74c3acefd2c5513</originalsourceid><addsrcrecordid>eNqFkc9uEzEQh1cIREPhAbggX-DUDf6za-9yQ1ULlSpxoJytqXc2ceW1g-1NlHfpw-KkkXLkNNLMN9-M9Kuqj4wuGy77r_CUp_WSU8qXUi65bF5VC9YoWTPZtK-rBS2TupdCXVTvUnqilHWcsbfVBeNM9Jz1i-r5N4yY9wT8QOw0zT6s0FtjSyuMJGOOsAWHPhNnt1hDzuhnyDiQAf1qRrIFY6zHRKwnD2uwBIbZZbINbvYZMaZvJAaHB1vCGPJ-g8QEb4oyQrbBX5FjvTq-MJVduyn4EBKm99WbEVzCD6d6Wf25vXm4_lnf__pxd_39vjZNr3ItJGJLWxwNqkEIYSgoqhj0j3wsjV4Mqmu7ZmwbMVAlD-PGCDA4Dty0LROX1ZcX7yaGvzOmrCebDDoHHsOctGK9kMXwX5B1qucN4wVkL6CJIaWIo95EO0Hca0b1ITt9zE4fstNS6pJd2fl0ks-PEw7njVNYBfh8AiAZcGMEb2w6c0L1TdfxM7e2q_XORtRpAueKlundblfOiePBf1XNtAk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18792412</pqid></control><display><type>article</type><title>Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Sabchareon, A ; Lang, J ; Chanthavanich, P ; Yoksan, S ; Forrat, R ; Attanath, P ; Sirivichayakul, C ; Pengsaa, K ; Pojjaroen-Anant, C ; Chokejindachai, W ; Jagsudee, A ; Saluzzo, JF ; Bhamarapravati, N</creator><creatorcontrib>Sabchareon, A ; Lang, J ; Chanthavanich, P ; Yoksan, S ; Forrat, R ; Attanath, P ; Sirivichayakul, C ; Pengsaa, K ; Pojjaroen-Anant, C ; Chokejindachai, W ; Jagsudee, A ; Saluzzo, JF ; Bhamarapravati, N</creatorcontrib><description>Dengue fever, caused by four serotypes of a mosquito-borne virus, is a growing problem in tropical countries. Currently, there is no treatment or vaccine. We evaluated safety and immunogenicity of two doses, given six months apart, of seven formulations of dengue tetravalent live-attenuated vaccine (containing different concentrations of the component viruses) versus placebo in 59 flavivirus-seronegative Thai adults. The first dose was the more reactogenic. Most volunteers experienced clinically moderate fever, headache, myalgia, eye pain or rash 7-11 days after injection, generally lasting three days or less. Modest decreases in platelets and neutrophils were observed. After one dose, 58% of dengue recipients seroconverted (neutralizing antibody level > or = 1:10) against > or = 3 serotypes; 35% seroconverted against all four. After the second dose, seroconversion was 76% and 71%, respectively. All subjects seroconverted to serotype 3 after one dose. Serotype 4 elicited the lowest primary response but the highest increase in seroconversion after the second dose.</description><identifier>ISSN: 0002-9637</identifier><identifier>EISSN: 1476-1645</identifier><identifier>DOI: 10.4269/ajtmh.2002.66.264</identifier><identifier>PMID: 12139219</identifier><identifier>CODEN: AJTHAB</identifier><language>eng</language><publisher>Lawrence, KS: ASTMH</publisher><subject>Adolescent ; Adult ; Antibodies, Viral - blood ; Arboviroses ; Biological and medical sciences ; Dengue - immunology ; Dengue - prevention & control ; Dengue fevers ; Dengue Virus - classification ; Dengue Virus - immunology ; Double-Blind Method ; Female ; Human viral diseases ; Humans ; Immunization Schedule ; Infectious diseases ; Male ; Medical sciences ; Serotyping ; Thailand ; Tropical medicine ; Tropical viral diseases ; Vaccines, Attenuated - administration & dosage ; Vaccines, Attenuated - adverse effects ; Vaccines, Attenuated - immunology ; Viral diseases ; Viral Vaccines - administration & dosage ; Viral Vaccines - adverse effects ; Viral Vaccines - immunology ; Viremia - virology</subject><ispartof>The American journal of tropical medicine and hygiene, 2002-03, Vol.66 (3), p.264-272</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-36ee505efce7d333c0a7071a9b2f7d393d78584f543d076c0a74c3acefd2c5513</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13794882$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12139219$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sabchareon, A</creatorcontrib><creatorcontrib>Lang, J</creatorcontrib><creatorcontrib>Chanthavanich, P</creatorcontrib><creatorcontrib>Yoksan, S</creatorcontrib><creatorcontrib>Forrat, R</creatorcontrib><creatorcontrib>Attanath, P</creatorcontrib><creatorcontrib>Sirivichayakul, C</creatorcontrib><creatorcontrib>Pengsaa, K</creatorcontrib><creatorcontrib>Pojjaroen-Anant, C</creatorcontrib><creatorcontrib>Chokejindachai, W</creatorcontrib><creatorcontrib>Jagsudee, A</creatorcontrib><creatorcontrib>Saluzzo, JF</creatorcontrib><creatorcontrib>Bhamarapravati, N</creatorcontrib><title>Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses</title><title>The American journal of tropical medicine and hygiene</title><addtitle>Am J Trop Med Hyg</addtitle><description>Dengue fever, caused by four serotypes of a mosquito-borne virus, is a growing problem in tropical countries. Currently, there is no treatment or vaccine. We evaluated safety and immunogenicity of two doses, given six months apart, of seven formulations of dengue tetravalent live-attenuated vaccine (containing different concentrations of the component viruses) versus placebo in 59 flavivirus-seronegative Thai adults. The first dose was the more reactogenic. Most volunteers experienced clinically moderate fever, headache, myalgia, eye pain or rash 7-11 days after injection, generally lasting three days or less. Modest decreases in platelets and neutrophils were observed. After one dose, 58% of dengue recipients seroconverted (neutralizing antibody level > or = 1:10) against > or = 3 serotypes; 35% seroconverted against all four. After the second dose, seroconversion was 76% and 71%, respectively. All subjects seroconverted to serotype 3 after one dose. Serotype 4 elicited the lowest primary response but the highest increase in seroconversion after the second dose.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antibodies, Viral - blood</subject><subject>Arboviroses</subject><subject>Biological and medical sciences</subject><subject>Dengue - immunology</subject><subject>Dengue - prevention & control</subject><subject>Dengue fevers</subject><subject>Dengue Virus - classification</subject><subject>Dengue Virus - immunology</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunization Schedule</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Serotyping</subject><subject>Thailand</subject><subject>Tropical medicine</subject><subject>Tropical viral diseases</subject><subject>Vaccines, Attenuated - administration & dosage</subject><subject>Vaccines, Attenuated - adverse effects</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Viral diseases</subject><subject>Viral Vaccines - administration & dosage</subject><subject>Viral Vaccines - adverse effects</subject><subject>Viral Vaccines - immunology</subject><subject>Viremia - virology</subject><issn>0002-9637</issn><issn>1476-1645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9uEzEQh1cIREPhAbggX-DUDf6za-9yQ1ULlSpxoJytqXc2ceW1g-1NlHfpw-KkkXLkNNLMN9-M9Kuqj4wuGy77r_CUp_WSU8qXUi65bF5VC9YoWTPZtK-rBS2TupdCXVTvUnqilHWcsbfVBeNM9Jz1i-r5N4yY9wT8QOw0zT6s0FtjSyuMJGOOsAWHPhNnt1hDzuhnyDiQAf1qRrIFY6zHRKwnD2uwBIbZZbINbvYZMaZvJAaHB1vCGPJ-g8QEb4oyQrbBX5FjvTq-MJVduyn4EBKm99WbEVzCD6d6Wf25vXm4_lnf__pxd_39vjZNr3ItJGJLWxwNqkEIYSgoqhj0j3wsjV4Mqmu7ZmwbMVAlD-PGCDA4Dty0LROX1ZcX7yaGvzOmrCebDDoHHsOctGK9kMXwX5B1qucN4wVkL6CJIaWIo95EO0Hca0b1ITt9zE4fstNS6pJd2fl0ks-PEw7njVNYBfh8AiAZcGMEb2w6c0L1TdfxM7e2q_XORtRpAueKlundblfOiePBf1XNtAk</recordid><startdate>20020301</startdate><enddate>20020301</enddate><creator>Sabchareon, A</creator><creator>Lang, J</creator><creator>Chanthavanich, P</creator><creator>Yoksan, S</creator><creator>Forrat, R</creator><creator>Attanath, P</creator><creator>Sirivichayakul, C</creator><creator>Pengsaa, K</creator><creator>Pojjaroen-Anant, C</creator><creator>Chokejindachai, W</creator><creator>Jagsudee, A</creator><creator>Saluzzo, JF</creator><creator>Bhamarapravati, N</creator><general>ASTMH</general><general>Allen Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U2</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20020301</creationdate><title>Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses</title><author>Sabchareon, A ; Lang, J ; Chanthavanich, P ; Yoksan, S ; Forrat, R ; Attanath, P ; Sirivichayakul, C ; Pengsaa, K ; Pojjaroen-Anant, C ; Chokejindachai, W ; Jagsudee, A ; Saluzzo, JF ; Bhamarapravati, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-36ee505efce7d333c0a7071a9b2f7d393d78584f543d076c0a74c3acefd2c5513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antibodies, Viral - blood</topic><topic>Arboviroses</topic><topic>Biological and medical sciences</topic><topic>Dengue - immunology</topic><topic>Dengue - prevention & control</topic><topic>Dengue fevers</topic><topic>Dengue Virus - classification</topic><topic>Dengue Virus - immunology</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunization Schedule</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Serotyping</topic><topic>Thailand</topic><topic>Tropical medicine</topic><topic>Tropical viral diseases</topic><topic>Vaccines, Attenuated - administration & dosage</topic><topic>Vaccines, Attenuated - adverse effects</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Viral diseases</topic><topic>Viral Vaccines - administration & dosage</topic><topic>Viral Vaccines - adverse effects</topic><topic>Viral Vaccines - immunology</topic><topic>Viremia - virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sabchareon, A</creatorcontrib><creatorcontrib>Lang, J</creatorcontrib><creatorcontrib>Chanthavanich, P</creatorcontrib><creatorcontrib>Yoksan, S</creatorcontrib><creatorcontrib>Forrat, R</creatorcontrib><creatorcontrib>Attanath, P</creatorcontrib><creatorcontrib>Sirivichayakul, C</creatorcontrib><creatorcontrib>Pengsaa, K</creatorcontrib><creatorcontrib>Pojjaroen-Anant, C</creatorcontrib><creatorcontrib>Chokejindachai, W</creatorcontrib><creatorcontrib>Jagsudee, A</creatorcontrib><creatorcontrib>Saluzzo, JF</creatorcontrib><creatorcontrib>Bhamarapravati, N</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of tropical medicine and hygiene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sabchareon, A</au><au>Lang, J</au><au>Chanthavanich, P</au><au>Yoksan, S</au><au>Forrat, R</au><au>Attanath, P</au><au>Sirivichayakul, C</au><au>Pengsaa, K</au><au>Pojjaroen-Anant, C</au><au>Chokejindachai, W</au><au>Jagsudee, A</au><au>Saluzzo, JF</au><au>Bhamarapravati, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses</atitle><jtitle>The American journal of tropical medicine and hygiene</jtitle><addtitle>Am J Trop Med Hyg</addtitle><date>2002-03-01</date><risdate>2002</risdate><volume>66</volume><issue>3</issue><spage>264</spage><epage>272</epage><pages>264-272</pages><issn>0002-9637</issn><eissn>1476-1645</eissn><coden>AJTHAB</coden><abstract>Dengue fever, caused by four serotypes of a mosquito-borne virus, is a growing problem in tropical countries. Currently, there is no treatment or vaccine. We evaluated safety and immunogenicity of two doses, given six months apart, of seven formulations of dengue tetravalent live-attenuated vaccine (containing different concentrations of the component viruses) versus placebo in 59 flavivirus-seronegative Thai adults. The first dose was the more reactogenic. Most volunteers experienced clinically moderate fever, headache, myalgia, eye pain or rash 7-11 days after injection, generally lasting three days or less. Modest decreases in platelets and neutrophils were observed. After one dose, 58% of dengue recipients seroconverted (neutralizing antibody level > or = 1:10) against > or = 3 serotypes; 35% seroconverted against all four. After the second dose, seroconversion was 76% and 71%, respectively. All subjects seroconverted to serotype 3 after one dose. Serotype 4 elicited the lowest primary response but the highest increase in seroconversion after the second dose.</abstract><cop>Lawrence, KS</cop><pub>ASTMH</pub><pmid>12139219</pmid><doi>10.4269/ajtmh.2002.66.264</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9637 |
| ispartof | The American journal of tropical medicine and hygiene, 2002-03, Vol.66 (3), p.264-272 |
| issn | 0002-9637 1476-1645 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71936584 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Antibodies, Viral - blood Arboviroses Biological and medical sciences Dengue - immunology Dengue - prevention & control Dengue fevers Dengue Virus - classification Dengue Virus - immunology Double-Blind Method Female Human viral diseases Humans Immunization Schedule Infectious diseases Male Medical sciences Serotyping Thailand Tropical medicine Tropical viral diseases Vaccines, Attenuated - administration & dosage Vaccines, Attenuated - adverse effects Vaccines, Attenuated - immunology Viral diseases Viral Vaccines - administration & dosage Viral Vaccines - adverse effects Viral Vaccines - immunology Viremia - virology |
| title | Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T23%3A09%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20immunogenicity%20of%20tetravalent%20live-attenuated%20dengue%20vaccines%20in%20Thai%20adult%20volunteers:%20role%20of%20serotype%20concentration,%20ratio,%20and%20multiple%20doses&rft.jtitle=The%20American%20journal%20of%20tropical%20medicine%20and%20hygiene&rft.au=Sabchareon,%20A&rft.date=2002-03-01&rft.volume=66&rft.issue=3&rft.spage=264&rft.epage=272&rft.pages=264-272&rft.issn=0002-9637&rft.eissn=1476-1645&rft.coden=AJTHAB&rft_id=info:doi/10.4269/ajtmh.2002.66.264&rft_dat=%3Cproquest_cross%3E71936584%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18792412&rft_id=info:pmid/12139219&rfr_iscdi=true |